Genmab — Maj 2016
-
Elo: The co-primary endpoints of this study, progression-free survival (PFS) as assessed by hazard ratio (HR) and overall response rate (ORR), were achieved, with extended follow-up data showing a 53% relative improvement in PFS rate at three years (23% versus 15%). Additionally, a pre-specified interim analysis for overall survival (OS) found a positive trend favoring the Empliciti combination versus Rd alone (HR=0.77 [95% CI: 0.61, 0.97, p=0.0257])
-
with 19% of pts with ≥3 prior lines of therapy
-
så der var også nogle syge patienter med i studiet
-
Elo 78 % ORR. Dara 93 % og så en sindssyg 43 % CR oveni. Elo kan godt gå hjem nu
-
VGPR var hele 76 % !!! med Dara mod kun 44% i kontrolarmen
-
-
Kursen er nu 1094
-
Prøv lige at tjekke PFS grafen for Dara. 80 % af patienter er stadig med efter 12 måneder !! Efter 21 måneder er de stadig omkring 75. Der går lang tid endnu før de rammer 50 og dermed finder median PFS..
-
Det er nok også det der taler for at de 78 % VGPR gør at der med tiden bliver højere end 43 % CR. Når patienterne kan leve så længe med et VGPR er de nok i praksis reelt et CR når der bliver lavet bone marrow biopsi
-
Den sidste skulder er så dannet i den aktuelle skulder-hoved-skulder formation.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
